From Sprouting Angiogenesis to Erythrocytes Generation by Cancer Stem Cells: Evolving Concepts in Tumor Microcirculation

Table 1

List of FDA approved antiangiogenic agents.

Antiangiogenic agent	Pharmacological class	FDA approvals
Bevacizumab	Monoclonal antibody	(i) Metastatic colorectal cancer; (ii) Metastatic non-small nonsquamous cell lung carcinoma; (iii) Renal cell carcinoma (in combination with interferon-alpha immunotherapy); (iv) Glioblastoma
Pazopanib	Multireceptor tyrosine kinase inhibitor	(i) Renal cell carcinoma; (ii) Soft tissue sarcoma
Sunitinib	Multireceptor tyrosine kinase inhibitor	(i) Second line in gastrointestinal stromal tumor after imatinib exposure; (ii) Advanced renal cell carcinoma; (iii) Progressive pancreatic neuroendocrine tumors
Vandetanib	Multireceptor tyrosine kinase inhibitor	Medullary thyroid carcinoma
Sorafenib	Multireceptor tyrosine kinase inhibitor	(i) Renal cell carcinoma; (ii) Hepatocellular carcinoma
Ziv-aflibercept	Monoclonal antibody	Second line in metastatic colorectal cancer
Ramucirumab	Monoclonal antibody	Metastatic esophageal, gastric, or gastroesophageal junction carcinoma